EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Elexacaftor/tezacaftor/ivacaftor en adultos con fibrosis quística: resultados a 3 años en práctica clínica real

Ester Zamarrón de Lucas, Clara Crespo Catalán, Belén Romero Campos, Belén Sanz Sanjosé, María Longás Ouzzine, Cindy Stephania Aponte Guevara, Rodolfo Álvarez-Sala Walther, María Concepción Prados Sánchez

Medicina Clínica · 2026-08 · 166 (8) · 107448

DOI: 10.1016/j.medcli.2026.107448 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medicina Clínica, 2026-08. Verfasst von Ester Zamarrón de Lucas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España. Electronic address: Ester.zam…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Quinolones, Indoles. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION CFTR modulators have significantly changed the prognosis of cystic fibrosis (CF), although data on their long-term clinical and microbiological impact in adults in real-world practice remain limited. OBJECTIVE To analyze the clinical, functional, and microbiological outcomes at 36 months in adults with CF treated with elexacaftor/tezacaftor/ivacaftor (ETI). METHODS A longitudinal observational study was conducted in adults with CF. Lung function, number of exacerbations, weight, and sputum cultures were assessed at baseline and at 12, 24, and 36 months after initiation of ETI. RESULTS A total of 55 patients were included (43.6% female; mean age 32±13 years). FEV1 improved at 12 months and remained stable at 36 months. Exacerbations decreased, and weight increased progressively. The proportion of patients with potentially pathogenic microorganisms decreased from 93.1% at baseline to 36.2% at 36 months. Patients without microbiological isolation showed better lung function and fewer exacerbations. CONCLUSIONS In real-world clinical practice, ETI is associated with improvements in lung function, weight, and exacerbations, as well as a reduction in the isolation of potentially pathogenic microorganisms in sputum at 36 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBenzodioxolesQuinolonesIndolesAminophenolsPyrrolidinesChloride Channel AgonistsPyridinesHumansFemaleAdultLongitudinal StudiesMaleTreatment OutcomeDrug CombinationsYoung AdultSputumForced Expiratory VolumeTime FactorsPyrazolesQuinolines

Stichwörter der Autor:innen

Cystic fibrosisEvoluciónEvolutionFibrosis quísticaMicrobiologyMicrobiologíaModuladoresModulators

Substanzen

BenzodioxolesQuinolonesIndolesAminophenolsDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationPyrrolidinesChloride Channel AgonistsPyridinesPyrazoles

Autor:innen und Institutionen

  • Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España. Electronic address: Ester.zamarron@gmail.com.
  • Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España.

Zitieren

APA

Zamarrón de Lucas, E., Crespo Catalán, C., Romero Campos, B., Sanz Sanjosé, B., Longás Ouzzine, M., Aponte Guevara, C. S., Álvarez-Sala Walther, R., & Prados Sánchez, M. C. (2026). Elexacaftor/tezacaftor/ivacaftor en adultos con fibrosis quística: resultados a 3 años en práctica clínica real. Medicina Clínica, 166(8), 107448. https://doi.org/10.1016/j.medcli.2026.107448

Vancouver

Zamarrón de Lucas E, Crespo Catalán C, Romero Campos B, Sanz Sanjosé B, Longás Ouzzine M, Aponte Guevara CS, et al. Elexacaftor/tezacaftor/ivacaftor en adultos con fibrosis quística: resultados a 3 años en práctica clínica real. Medicina Clínica. 2026;166(8):107448. doi:10.1016/j.medcli.2026.107448

BibTeX
@article{ZamarrndeLucas2026,
  author = {Zamarrón de Lucas, Ester and Crespo Catalán, Clara and Romero Campos, Belén and Sanz Sanjosé, Belén and Longás Ouzzine, María and Aponte Guevara, Cindy Stephania and Álvarez-Sala Walther, Rodolfo and Prados Sánchez, María Concepción},
  title = {Elexacaftor/tezacaftor/ivacaftor en adultos con fibrosis quística: resultados a 3 años en práctica clínica real},
  journal = {Medicina Clínica},
  year = {2026},
  volume = {166},
  number = {8},
  pages = {107448},
  doi = {10.1016/j.medcli.2026.107448}
}
Kostenlos starten →